Congratulations to Daoqun Group on obtaining approval for 100mg aspirin enteric coated tablets on February 26, 2024! This is the second aspirin approval obtained by the group since June 2023.

Aspirin (also known as acetylsalicylic acid) is a non steroidal anti-inflammatory drug with a history of 125 years, and is one of the world's three classic drugs along with penicillin and diazepam.

Since its launch, aspirin has been extensively tested in clinical trials to confirm its pharmacological effects and has been widely used in clinical practice.

Daoqun Group, founded in 2008, is based in East China. Its business covers three major areas: drug sales research and development, medical device sales research and development, and Internet+Great Health. Its business channels cover the whole country.

The group has always adhered to the corporate mission of "assisting medical care and safeguarding health". With the combination of innovation and experience, a strict and standardized quality management system, and professional and rigorous efficient research and development, it has successfully obtained this one-time evaluation approval.

As of now, Daoqun Group has three self owned licensed drugs, including Jinqi Jiangtang Capsules.

In the future, the group will actively deepen cooperation with industry partners, launch more independently developed products into the pharmaceutical market, strive to promote the development of high-quality domestic drugs, and make more contributions to the development of the medical industry.